Authors:
Villalona-Calero, MA
Blum, JL
Jones, SE
Diab, S
Elledge, R
Khoury, P
Von Hoff, D
Kraynak, M
Moczygemba, J
Kromelis, P
Griffin, T
Rowinsky, EK
Citation: Ma. Villalona-calero et al., A phase I and pharmacologic study of capecitabine and paclitaxel in breastcancer patients, ANN ONCOL, 12(5), 2001, pp. 605-614
Authors:
Rha, SY
Izbicka, E
Lawrence, R
Davidson, K
Sun, DK
Moyer, MP
Roodman, GD
Hurley, L
Von Hoff, D
Citation: Sy. Rha et al., Effect of telomere and telomerase interactive agents on human tumor and normal cell lines, CLIN CANC R, 6(3), 2000, pp. 987-993
Authors:
Nemunaitis, J
Holmlund, JT
Kraynak, M
Richards, D
Bruce, J
Ognoskie, N
Kwoh, TJ
Geary, R
Dorr, A
Von Hoff, D
Eckhard, SG
Citation: J. Nemunaitis et al., Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer, J CL ONCOL, 17(11), 1999, pp. 3586-3595
Authors:
Hensley, ML
Schuchter, LM
Lindley, C
Meropol, NJ
Cohen, GI
Broder, G
Gradishar, WJ
Green, DM
Langdon, RJ
Mitchell, B
Negrin, R
Szatrowski, TP
Thigpen, JT
Von Hoff, D
Wasserman, TH
Winer, EP
Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Authors:
Weitman, S
Mangold, G
Marty, J
Dexter, D
Hilsenbeck, S
Rake, J
Juniewicz, P
Von Hoff, D
Citation: S. Weitman et al., Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft, CANC CHEMOT, 43(5), 1999, pp. 402-408
Authors:
Del Poeta, M
Chen, SF
Von Hoff, D
Dykstra, CC
Wani, MC
Manikumar, G
Heitman, J
Wall, ME
Perfect, JR
Citation: M. Del Poeta et al., Comparison of in vitro activities of camptothecin and nitidine derivativesagainst fungal and cancer cells, ANTIM AG CH, 43(12), 1999, pp. 2862-2868